Biosante Pharmaceuticals Inc (NASDAQ: BPAX) shares advanced 7.97% to $3.25 in the pre-market session. BPAX reported lifting of clinical hold on the GVAX Prostate Cancer Vaccine (GVAX Prostate) by FDA. Link: http://www.benzinga.com/markets/11/06/1140398/benzingas-top-pre-market-nasdaq-gainers